GSK presents Hibsago and efimosfermin results at AASLD 2026
- B‑Well Phase III will report functional cure rates 48 weeks after all HBV treatment is stopped (Oral presentation #0266).
- Hibsago (bepirovirsen) has recent US approval and will be the subject of multiple analyses on HBsAg reduction, week‑12 predictors and retreatment modelling.
- Efimosfermin Phase II shows non‑invasive fibrosis improvement signals up to 52 weeks in MASH—including compensated cirrhosis (F4)—supporting ongoing Phase III ZENITH (F2–3) and NEBULA (F4) trials.
- GSK will present 21 abstracts across CHB, MASH and ALD; liver diseases account for roughly 2 million deaths annually and CHB affects over 240 million people.
Event and scope
GSK will present 21 abstracts from its hepatology portfolio at AASLD The Liver Meeting® 2026 in Denver (5–9 November), covering chronic hepatitis B (CHB), metabolic dysfunction‑associated steatohepatitis (MASH) and alcohol‑related liver disease (ALD).
Bepirovirsen (Hibsago) data
Following recent US approval, long‑term datasets from the B‑Well Phase III programme will be presented, including functional cure rates 48 weeks after all HBV treatment is stopped (Oral #0266), HBsAg dynamics in non‑responders (Poster #4151), week‑12 and end‑of‑treatment HBsAg as predictors of functional cure (Oral #0260), and predictive modelling of retreatment in relapsing patients (Poster #4163). A retrospective cohort analysis from China on HBsAg loss and reduced long‑term risk of cirrhosis and hepatocellular carcinoma will also be shared (Poster #4045).
Efimosfermin data
Phase II results will show improvement in non‑invasive fibrosis markers up to 52 weeks in MASH patients with moderate‑to‑advanced fibrosis or compensated cirrhosis (Poster #2299), and an analysis linking liver fat reduction to fibrosis improvement in F2–F3 patients (Poster #5025). Ongoing Phase III ZENITH (F2–3) and NEBULA (F4) trials are in progress (Posters #3576, #3558).
Clinical context
The programme targets high‑burden indications: CHB affects over 240 million people and contributes substantially to liver cancer, while CHB, MASH and ALD together drive the majority of liver‑related deaths globally.
Source: GSK